RecruitingEarly Phase 1NCT07197450

Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism

Efficacy and Safety of mRNA Drug XH02 in the Treatment of Adult Hypoparathyroidism

Sponsor

Peking Union Medical College Hospital

Enrollment

6 participants

Start Date

May 20, 2025

Study Type

INTERVENTIONAL

Conditions

Hypoparathyroidism

Summary

This study aims to evaluate the safety and efficacy of a novel PTH replacement therapy drug in patients with hypoparathyroidism. The drug is an mRNA drug which will be translated into PTH after intravenous administration, to achieve the therapeutic effect.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called intravenous administration of PTH1-84 mRNA for people with hypoparathyroidism. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGintravenous administration of PTH1-84 mRNA

intravenous administration of PTH1-84 mRNA

Locations(1)

Peking Union Medical College Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07197450

Related Trials

A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism

NCT077067641 location

A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism

NCT076994712 locations

A Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism

NCT075402861 location

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

NCT070835571 location

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

NCT070819973 locations